Physician profile

Mark L Fruiterman

Endocrinology, Diabetes & Metabolism · Albany, NY

NPI 1609879709

$1,157.59

in general payments reported to CMS, 2019-2025

18 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$19.34

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Insulet Corporation $232.35 2019
Novo Nordisk INC $208.60 2019-2020
Astrazeneca Pharmaceuticals Lp $131.61 2019-2020
Ipsen Biopharmaceuticals, INC $113.48 2019-2022
Abbott Laboratories $66.32 2019
Corcept Therapeutics $66.03 2019-2020
Abbvie INC. $50.81 2019-2020
Sanofi-Aventis U.S. LLC $46.29 2019-2020
Janssen Pharmaceuticals, INC $42.92 2019
Amgen INC. $39.40 2019-2020
Kowa Pharmaceuticals America, INC. $31.57 2019
Dexcom, INC. $30.17 2019-2020
Mannkind Corporation $25.49 2019-2020
Rgh Enterprises LLC $19.34 2024
Lifescan, INC. $16.45 2020
Show all 18 companies
CompanyGeneral paymentsYearsTop products
Ibsa Pharma INC. $12.91 2019
Lilly USA, LLC $11.97 2019
Boehringer Ingelheim Pharmaceuticals, INC. $11.88 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark L Fruiterman

$1,157.59

in general payments reported 2019-2025

Years
2019-2024
Top company
Insulet Corporation

https://glasscript.com/doctor/299271/mark-l-fruiterman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.